Tumor Necrosis Factor (Cachectin) in Human Visceral Leishmaniasis
High tumor necrosis factor-α (TNFα) levels were present in the serum of24 of28 active visceral leishmaniasis (VL) patients (142.9 ± 113.9pg/ml, mean ± SD), whereas levels were not elevated in 26 of 30 patients with cryptic leishmanial infection (16 asymptomatic, 4 with self-healing subclinical infec...
Gespeichert in:
| Veröffentlicht in: | The Journal of infectious diseases 1991-04, Vol.163 (4), p.853-857 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 857 |
|---|---|
| container_issue | 4 |
| container_start_page | 853 |
| container_title | The Journal of infectious diseases |
| container_volume | 163 |
| creator | Barral-Netto, M. Badaró, R. Barral, A. Almeida, R. P. Santos, S. B. Badaró, F. Pedral-Sampaio, D. Carvalho, E. M. Falcoff, E. Falcoff, R. |
| description | High tumor necrosis factor-α (TNFα) levels were present in the serum of24 of28 active visceral leishmaniasis (VL) patients (142.9 ± 113.9pg/ml, mean ± SD), whereas levels were not elevated in 26 of 30 patients with cryptic leishmanial infection (16 asymptomatic, 4 with self-healing subclinical infection, and 10 posttreatment VL cases). Serum TNFα levels were also not elevated in 15 normal volunteers (11.3 ± 15.6 pg/ml) and in 10 patients with tegumentary leishmaniasis (19.1 ± 10.8pg/ml). Leishmanial infection of human monocyte-derived macrophages enhanced the basal TNFα production by these cells, and this effect was further potentiated by treatment with recombinant interferon-γ, After effectivetreatment ofVL patients, serumTNFα levelsdropped rapidly (129 ± 112 vs. 9 ± 13 pg/ml in 10 days), even before clinical parameters such as spleen size or parasitism, white blood cell count, or levels of hemoglobin returned to normal values. On the other hand, patients unresponsive to treatment remained with elevated levels (276 ± 69 vs. 155 ± 71 pg/ml in 10 days). Thus, serum TNFα levels in VL patients are a good parameter to monitor in determining host response to therapy. |
| doi_str_mv | 10.1093/infdis/163.4.853 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_80501316</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>30132336</jstor_id><sourcerecordid>30132336</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-d19b4fe70ef184e3c3e144ab1df002a4599241bf7def66b3a514db864c5f262e3</originalsourceid><addsrcrecordid>eNqFkE1P4zAQhq0VCAq7972slAsrOKR4Mo6THFFFW1BVhMR-aC-W49iqS5KydiLBv8clVXtEPlj2-6GZh5DvQMdAC7y2ramsvwaOYzbOU_xCRpBiFnMOeERGlCZJDHlRnJIz79eUUoY8OyEnUFBAxBG5eeqbjYuWWrmNtz6aStWF9-VEqpVWnW2vIttG876RbfTbeqWdrKOFtn4VfqwMka_k2Mja62-7-5z8mt4-Tebx4mF2N7lZxIpB2sUVFCUzOqPaQM40KtTAmCyhMmFKydKiSBiUJqu04bxEmQKrypwzlZqEJxrPyc-h98Vt_vfad6LZzlPXstWb3oucpmGnQOIzI3BKeZ4VwUgH43Z377QRL8420r0JoGKLVwx4QwIFEwFviPzYdfdlo6tDYOAZ9IudLr2StXGyVaHgYMs-zqFn7QPuvY6hJUHc7hAPuvWdft3r0j0LnmGWivnff-JxNr-f_lnmYonvNQ-b_w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16006879</pqid></control><display><type>article</type><title>Tumor Necrosis Factor (Cachectin) in Human Visceral Leishmaniasis</title><source>MEDLINE</source><source>JSTOR Archive Collection A-Z Listing</source><creator>Barral-Netto, M. ; Badaró, R. ; Barral, A. ; Almeida, R. P. ; Santos, S. B. ; Badaró, F. ; Pedral-Sampaio, D. ; Carvalho, E. M. ; Falcoff, E. ; Falcoff, R.</creator><creatorcontrib>Barral-Netto, M. ; Badaró, R. ; Barral, A. ; Almeida, R. P. ; Santos, S. B. ; Badaró, F. ; Pedral-Sampaio, D. ; Carvalho, E. M. ; Falcoff, E. ; Falcoff, R.</creatorcontrib><description>High tumor necrosis factor-α (TNFα) levels were present in the serum of24 of28 active visceral leishmaniasis (VL) patients (142.9 ± 113.9pg/ml, mean ± SD), whereas levels were not elevated in 26 of 30 patients with cryptic leishmanial infection (16 asymptomatic, 4 with self-healing subclinical infection, and 10 posttreatment VL cases). Serum TNFα levels were also not elevated in 15 normal volunteers (11.3 ± 15.6 pg/ml) and in 10 patients with tegumentary leishmaniasis (19.1 ± 10.8pg/ml). Leishmanial infection of human monocyte-derived macrophages enhanced the basal TNFα production by these cells, and this effect was further potentiated by treatment with recombinant interferon-γ, After effectivetreatment ofVL patients, serumTNFα levelsdropped rapidly (129 ± 112 vs. 9 ± 13 pg/ml in 10 days), even before clinical parameters such as spleen size or parasitism, white blood cell count, or levels of hemoglobin returned to normal values. On the other hand, patients unresponsive to treatment remained with elevated levels (276 ± 69 vs. 155 ± 71 pg/ml in 10 days). Thus, serum TNFα levels in VL patients are a good parameter to monitor in determining host response to therapy.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/163.4.853</identifier><identifier>PMID: 1901333</identifier><identifier>CODEN: JIDIAQ</identifier><language>eng</language><publisher>Chicago, IL: University Chicago Press</publisher><subject>Acute Disease ; Antimony - therapeutic use ; Antiprotozoal Agents - therapeutic use ; Biological and medical sciences ; Cells, Cultured ; Combined Modality Therapy ; Cutaneous leishmaniasis ; Female ; Human protozoal diseases ; Humans ; Infections ; Infectious diseases ; Interferon-gamma - pharmacology ; Interferon-gamma - therapeutic use ; Interferons ; Leishmaniasis, Visceral - blood ; Leishmaniasis, Visceral - diagnosis ; Leishmaniasis, Visceral - therapy ; Leshmaniasis ; Macrophages ; Macrophages - drug effects ; Macrophages - parasitology ; Major Article ; Male ; Medical sciences ; Meglumine - therapeutic use ; Meglumine Antimoniate ; Necrosis ; Organometallic Compounds - therapeutic use ; Parasite hosts ; Parasites ; Parasitic diseases ; Parasitism ; Protozoal diseases ; Recombinant Proteins ; Tropical medicine ; Tumor Necrosis Factor-alpha - analysis ; Tumor necrosis factors ; Visceral leishmaniasis</subject><ispartof>The Journal of infectious diseases, 1991-04, Vol.163 (4), p.853-857</ispartof><rights>Copyright 1991 University of Chicago</rights><rights>1991 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-d19b4fe70ef184e3c3e144ab1df002a4599241bf7def66b3a514db864c5f262e3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/30132336$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/30132336$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,780,784,803,27924,27925,58017,58250</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19797979$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1901333$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Barral-Netto, M.</creatorcontrib><creatorcontrib>Badaró, R.</creatorcontrib><creatorcontrib>Barral, A.</creatorcontrib><creatorcontrib>Almeida, R. P.</creatorcontrib><creatorcontrib>Santos, S. B.</creatorcontrib><creatorcontrib>Badaró, F.</creatorcontrib><creatorcontrib>Pedral-Sampaio, D.</creatorcontrib><creatorcontrib>Carvalho, E. M.</creatorcontrib><creatorcontrib>Falcoff, E.</creatorcontrib><creatorcontrib>Falcoff, R.</creatorcontrib><title>Tumor Necrosis Factor (Cachectin) in Human Visceral Leishmaniasis</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>High tumor necrosis factor-α (TNFα) levels were present in the serum of24 of28 active visceral leishmaniasis (VL) patients (142.9 ± 113.9pg/ml, mean ± SD), whereas levels were not elevated in 26 of 30 patients with cryptic leishmanial infection (16 asymptomatic, 4 with self-healing subclinical infection, and 10 posttreatment VL cases). Serum TNFα levels were also not elevated in 15 normal volunteers (11.3 ± 15.6 pg/ml) and in 10 patients with tegumentary leishmaniasis (19.1 ± 10.8pg/ml). Leishmanial infection of human monocyte-derived macrophages enhanced the basal TNFα production by these cells, and this effect was further potentiated by treatment with recombinant interferon-γ, After effectivetreatment ofVL patients, serumTNFα levelsdropped rapidly (129 ± 112 vs. 9 ± 13 pg/ml in 10 days), even before clinical parameters such as spleen size or parasitism, white blood cell count, or levels of hemoglobin returned to normal values. On the other hand, patients unresponsive to treatment remained with elevated levels (276 ± 69 vs. 155 ± 71 pg/ml in 10 days). Thus, serum TNFα levels in VL patients are a good parameter to monitor in determining host response to therapy.</description><subject>Acute Disease</subject><subject>Antimony - therapeutic use</subject><subject>Antiprotozoal Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cells, Cultured</subject><subject>Combined Modality Therapy</subject><subject>Cutaneous leishmaniasis</subject><subject>Female</subject><subject>Human protozoal diseases</subject><subject>Humans</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Interferon-gamma - pharmacology</subject><subject>Interferon-gamma - therapeutic use</subject><subject>Interferons</subject><subject>Leishmaniasis, Visceral - blood</subject><subject>Leishmaniasis, Visceral - diagnosis</subject><subject>Leishmaniasis, Visceral - therapy</subject><subject>Leshmaniasis</subject><subject>Macrophages</subject><subject>Macrophages - drug effects</subject><subject>Macrophages - parasitology</subject><subject>Major Article</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Meglumine - therapeutic use</subject><subject>Meglumine Antimoniate</subject><subject>Necrosis</subject><subject>Organometallic Compounds - therapeutic use</subject><subject>Parasite hosts</subject><subject>Parasites</subject><subject>Parasitic diseases</subject><subject>Parasitism</subject><subject>Protozoal diseases</subject><subject>Recombinant Proteins</subject><subject>Tropical medicine</subject><subject>Tumor Necrosis Factor-alpha - analysis</subject><subject>Tumor necrosis factors</subject><subject>Visceral leishmaniasis</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1P4zAQhq0VCAq7972slAsrOKR4Mo6THFFFW1BVhMR-aC-W49iqS5KydiLBv8clVXtEPlj2-6GZh5DvQMdAC7y2ramsvwaOYzbOU_xCRpBiFnMOeERGlCZJDHlRnJIz79eUUoY8OyEnUFBAxBG5eeqbjYuWWrmNtz6aStWF9-VEqpVWnW2vIttG876RbfTbeqWdrKOFtn4VfqwMka_k2Mja62-7-5z8mt4-Tebx4mF2N7lZxIpB2sUVFCUzOqPaQM40KtTAmCyhMmFKydKiSBiUJqu04bxEmQKrypwzlZqEJxrPyc-h98Vt_vfad6LZzlPXstWb3oucpmGnQOIzI3BKeZ4VwUgH43Z377QRL8420r0JoGKLVwx4QwIFEwFviPzYdfdlo6tDYOAZ9IudLr2StXGyVaHgYMs-zqFn7QPuvY6hJUHc7hAPuvWdft3r0j0LnmGWivnff-JxNr-f_lnmYonvNQ-b_w</recordid><startdate>19910401</startdate><enddate>19910401</enddate><creator>Barral-Netto, M.</creator><creator>Badaró, R.</creator><creator>Barral, A.</creator><creator>Almeida, R. P.</creator><creator>Santos, S. B.</creator><creator>Badaró, F.</creator><creator>Pedral-Sampaio, D.</creator><creator>Carvalho, E. M.</creator><creator>Falcoff, E.</creator><creator>Falcoff, R.</creator><general>University Chicago Press</general><general>University of Chicago Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>M7N</scope><scope>7X8</scope></search><sort><creationdate>19910401</creationdate><title>Tumor Necrosis Factor (Cachectin) in Human Visceral Leishmaniasis</title><author>Barral-Netto, M. ; Badaró, R. ; Barral, A. ; Almeida, R. P. ; Santos, S. B. ; Badaró, F. ; Pedral-Sampaio, D. ; Carvalho, E. M. ; Falcoff, E. ; Falcoff, R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-d19b4fe70ef184e3c3e144ab1df002a4599241bf7def66b3a514db864c5f262e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Acute Disease</topic><topic>Antimony - therapeutic use</topic><topic>Antiprotozoal Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cells, Cultured</topic><topic>Combined Modality Therapy</topic><topic>Cutaneous leishmaniasis</topic><topic>Female</topic><topic>Human protozoal diseases</topic><topic>Humans</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Interferon-gamma - pharmacology</topic><topic>Interferon-gamma - therapeutic use</topic><topic>Interferons</topic><topic>Leishmaniasis, Visceral - blood</topic><topic>Leishmaniasis, Visceral - diagnosis</topic><topic>Leishmaniasis, Visceral - therapy</topic><topic>Leshmaniasis</topic><topic>Macrophages</topic><topic>Macrophages - drug effects</topic><topic>Macrophages - parasitology</topic><topic>Major Article</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Meglumine - therapeutic use</topic><topic>Meglumine Antimoniate</topic><topic>Necrosis</topic><topic>Organometallic Compounds - therapeutic use</topic><topic>Parasite hosts</topic><topic>Parasites</topic><topic>Parasitic diseases</topic><topic>Parasitism</topic><topic>Protozoal diseases</topic><topic>Recombinant Proteins</topic><topic>Tropical medicine</topic><topic>Tumor Necrosis Factor-alpha - analysis</topic><topic>Tumor necrosis factors</topic><topic>Visceral leishmaniasis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barral-Netto, M.</creatorcontrib><creatorcontrib>Badaró, R.</creatorcontrib><creatorcontrib>Barral, A.</creatorcontrib><creatorcontrib>Almeida, R. P.</creatorcontrib><creatorcontrib>Santos, S. B.</creatorcontrib><creatorcontrib>Badaró, F.</creatorcontrib><creatorcontrib>Pedral-Sampaio, D.</creatorcontrib><creatorcontrib>Carvalho, E. M.</creatorcontrib><creatorcontrib>Falcoff, E.</creatorcontrib><creatorcontrib>Falcoff, R.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barral-Netto, M.</au><au>Badaró, R.</au><au>Barral, A.</au><au>Almeida, R. P.</au><au>Santos, S. B.</au><au>Badaró, F.</au><au>Pedral-Sampaio, D.</au><au>Carvalho, E. M.</au><au>Falcoff, E.</au><au>Falcoff, R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tumor Necrosis Factor (Cachectin) in Human Visceral Leishmaniasis</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>1991-04-01</date><risdate>1991</risdate><volume>163</volume><issue>4</issue><spage>853</spage><epage>857</epage><pages>853-857</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><coden>JIDIAQ</coden><abstract>High tumor necrosis factor-α (TNFα) levels were present in the serum of24 of28 active visceral leishmaniasis (VL) patients (142.9 ± 113.9pg/ml, mean ± SD), whereas levels were not elevated in 26 of 30 patients with cryptic leishmanial infection (16 asymptomatic, 4 with self-healing subclinical infection, and 10 posttreatment VL cases). Serum TNFα levels were also not elevated in 15 normal volunteers (11.3 ± 15.6 pg/ml) and in 10 patients with tegumentary leishmaniasis (19.1 ± 10.8pg/ml). Leishmanial infection of human monocyte-derived macrophages enhanced the basal TNFα production by these cells, and this effect was further potentiated by treatment with recombinant interferon-γ, After effectivetreatment ofVL patients, serumTNFα levelsdropped rapidly (129 ± 112 vs. 9 ± 13 pg/ml in 10 days), even before clinical parameters such as spleen size or parasitism, white blood cell count, or levels of hemoglobin returned to normal values. On the other hand, patients unresponsive to treatment remained with elevated levels (276 ± 69 vs. 155 ± 71 pg/ml in 10 days). Thus, serum TNFα levels in VL patients are a good parameter to monitor in determining host response to therapy.</abstract><cop>Chicago, IL</cop><pub>University Chicago Press</pub><pmid>1901333</pmid><doi>10.1093/infdis/163.4.853</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1899 |
| ispartof | The Journal of infectious diseases, 1991-04, Vol.163 (4), p.853-857 |
| issn | 0022-1899 1537-6613 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80501316 |
| source | MEDLINE; JSTOR Archive Collection A-Z Listing |
| subjects | Acute Disease Antimony - therapeutic use Antiprotozoal Agents - therapeutic use Biological and medical sciences Cells, Cultured Combined Modality Therapy Cutaneous leishmaniasis Female Human protozoal diseases Humans Infections Infectious diseases Interferon-gamma - pharmacology Interferon-gamma - therapeutic use Interferons Leishmaniasis, Visceral - blood Leishmaniasis, Visceral - diagnosis Leishmaniasis, Visceral - therapy Leshmaniasis Macrophages Macrophages - drug effects Macrophages - parasitology Major Article Male Medical sciences Meglumine - therapeutic use Meglumine Antimoniate Necrosis Organometallic Compounds - therapeutic use Parasite hosts Parasites Parasitic diseases Parasitism Protozoal diseases Recombinant Proteins Tropical medicine Tumor Necrosis Factor-alpha - analysis Tumor necrosis factors Visceral leishmaniasis |
| title | Tumor Necrosis Factor (Cachectin) in Human Visceral Leishmaniasis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T05%3A59%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tumor%20Necrosis%20Factor%20(Cachectin)%20in%20Human%20Visceral%20Leishmaniasis&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Barral-Netto,%20M.&rft.date=1991-04-01&rft.volume=163&rft.issue=4&rft.spage=853&rft.epage=857&rft.pages=853-857&rft.issn=0022-1899&rft.eissn=1537-6613&rft.coden=JIDIAQ&rft_id=info:doi/10.1093/infdis/163.4.853&rft_dat=%3Cjstor_proqu%3E30132336%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16006879&rft_id=info:pmid/1901333&rft_jstor_id=30132336&rfr_iscdi=true |